Hikal vs Solara Active Pharma Sciences: Share Price, Comparison and Key Differences

Hikal vs Solara Active Pharma Sciences is a comparison API and specialty chemical investors look up when evaluating two listed Indian companies in the pharma API and crop protection chemical segment. Hikal Limited, a Mumbai-based company, manufactures pharma APIs and crop protection chemicals (herbicides, fungicides) for the global market. Solara Active Pharma Sciences, a Chennai-based company, is an API manufacturer that emerged from Strides-Shasun's merger and focuses on complex APIs for regulated markets. Both Hikal vs Solara Active Pharma Sciences are currently loss-making – investors should note this prominently before any investment decision.

This Hikal vs Solara Active Pharma Sciences article covers reach and market position, key products, latest declared results and stock valuation. All data is sourced from Groww and public company filings.

Reach and Market Position

In this Hikal vs Solara Active Pharma Sciences comparison, Hikal manufactures pharma APIs and crop protection chemicals for global pharma and agrochemical companies. Market capitalisation is Rs 2,800 Cr.

Click Here – Get Free Investment Predictions

Solara Active Pharma Sciences manufactures complex APIs including ibuprofen, metformin and other regulated-market APIs. Market capitalisation is Rs 2,400 Cr.

Key Products and Business Mix

For the Hikal vs Solara Active Pharma Sciences product breakdown, Hikal: Hikal earns from pharma APIs (antibiotics, antivirals) and agrochemical intermediates. EPS is -Rs 2.74 (loss-making). ROE is 3.03 percent (distorted by small losses). D/E 0.57. Hikal is currently loss-making. Investors should verify current financials before any investment decision.

Solara Active Pharma Sciences: Solara earns from complex pharma APIs for regulated markets. EPS is -Rs 0.34 (loss-making). ROE is -0.12 percent. D/E 0.55. Solara Active Pharma Sciences is currently loss-making. Investors should verify current financials before any investment decision.

Latest Results and Financial Data

On the Hikal vs Solara Active Pharma Sciences results front: Hikal has a market cap of Rs 2,800 Cr and is loss-making with EPS of -Rs 2.74. Hikal is 1.2 times larger than Solara on market cap. Both companies are in a challenging operational phase.

Solara Active Pharma Sciences has a market cap of Rs 2,400 Cr and is loss-making with EPS of -Rs 0.34 and ROE of -0.12 percent. Both Hikal vs Solara are loss-making companies in the API manufacturing segment.

Compare Hikal and Solara Active Pharma Sciences Fundamentals on the Univest Screener

Stock Performance and Valuation

Investors tracking the Hikal vs Solara Active Pharma Sciences comparison should verify current prices on NSE or BSE before trading. The Hikal vs Solara Active Pharma Sciences stock data below reflects the latest available figures from Groww and public company filings.

Hikal vs Solara Active Pharma at current valuations: Both are loss-making. Hikal trades at approximately Rs 2,800 Cr market cap (loss-making). Solara trades at approximately Rs 2,400 Cr market cap (loss-making). The two API companies are similar in market cap size. NEITHER company is profitable at this time – investors should exercise extreme caution.

Hikal vs Solara Active Pharma Sciences: Quick Comparison Table

The comparison table below summarises the key metrics side by side.

Parameter	Hikal	Solara Active Pharma Sciences
Sector	Pharma APIs + crop protection chemicals (dual business)	Complex pharma APIs for regulated markets (US, EU exports)
Market Cap	Rs 2,800 Cr	Rs 2,400 Cr
Profitability	LOSS-MAKING (EPS -2.74)	LOSS-MAKING (EPS -0.34)
ROE	3.03% (distorted)	−0.12% (losses)
Debt to Equity	0.57	0.55
Key Products	Pharma APIs + herbicides, fungicides	Ibuprofen, metformin, complex APIs
Status	Loss-making phase	Loss-making phase

Conclusion

The Hikal vs Solara Active Pharma Sciences comparison above covers reach, products, results and valuation. Hikal vs Solara Active Pharma Sciences covers two Indian API manufacturers both currently in loss-making phases. Hikal has pharma API and crop protection chemical businesses. Solara has complex API manufacturing focused on regulated market exports. Hikal vs Solara investors must note that both companies are currently loss-making, and investment decisions should be made with detailed review of each company's path to profitability, capex cycles and customer contracts. Consult a SEBI-registered advisor before investing in any loss-making company.

Download the Univest iOS App or Univest Android App to track Hikal and Solara Active Pharma Sciences live price and get daily stock recommendations.

Frequently Asked Questions

Is Hikal profitable?

Ans. No. Hikal is currently loss-making with EPS of -Rs 2.74. Investors should verify the latest quarterly results from exchange filings before any investment decision.

Is Solara Active Pharma profitable?

Ans. No. Solara Active Pharma Sciences is currently loss-making with EPS of -Rs 0.34 and ROE of -0.12 percent. Investors should review the latest financials from exchange filings carefully.

What does Hikal make?

Ans. Hikal manufactures pharma APIs for antibiotic and antiviral medicines and crop protection chemicals (herbicide, fungicide intermediates) for global agrochemical companies. It operates from Taloja and Jigani facilities.

What does Solara Active Pharma make?

Ans. Solara Active Pharma Sciences manufactures complex APIs including ibuprofen, metformin and other active ingredients for regulated market pharma companies in the US and Europe.

Are Hikal and Solara in Nifty 50?

Ans. Neither is in Nifty 50. Both are tracked in smaller indices.

Which is larger, Hikal or Solara?

Ans. Hikal at Rs 2,800 Cr is approximately 1.2 times larger than Solara Active Pharma Sciences at Rs 2,400 Cr.

Should I invest in loss-making pharma API companies?

Ans. Loss-making companies carry significantly higher risk than profitable ones. Investors should carefully review the reasons for losses, the path to profitability, management guidance and financial health before investing. Consult a SEBI-registered investment advisor.